Stayble Therapeutics

Stayble Therapeutics

Tillverkning av läkemedel

Stayble is a clinical stage pharmaceutical company developing STA363, a treatment for disc-related chronic low back pain

Om oss

Stayble is a clinical stage pharmaceutical company developing the injectable treatment STA363 for disc hernia. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once, and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development of the ongoing clinical phase 1b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from pain caused by disc hernia.

Bransch
Tillverkning av läkemedel
Företagsstorlek
2–10 anställda
Huvudkontor
Gothenburg
Typ
Partnerskap
Grundat
2015
Specialistområden
Pharmaceutical development och Chronic low back pain

Adresser

Anställda på Stayble Therapeutics

Uppdateringar

Liknande sidor

Finansiering

Stayble Therapeutics 5 rundor totalt

Senaste finansieringsrunda

Aktiekapital efter börsintroduktion

3 405 459,00 US$

Se mer info på crunchbase